Search results
Your search for Comprar returned no results
Showing 376 to 390 of 561 results for compare
Showing 376 to 390 of 561 results for compare
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in adults.
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)
NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus
Minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones (MIB138)
NICE has developed a medtech innovation briefing (MIB) on minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones .
Faecal microbiota transplant for recurrent Clostridioides difficile infection (HTG638)
Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridioides difficile infection.
Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.
Evidence-based recommendations on Prontosan for treating acute and chronic wounds.
This guideline covers organising and delivering end of life care services, which provide care and support in the final weeks and months of life (or for some conditions, years), and the planning and preparation for this. It aims to ensure that people have access to the care that they want and need in all care settings. It also includes advice on services for carers.
NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging .
Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)
Evidence-based recommendations on mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma in adults.
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)
Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on nivolumab (Opdivo) for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.